miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor

被引:58
作者
Iida, Keiichiro [1 ]
Fukushi, Jun-ichi [1 ]
Matsumoto, Yoshihiro [1 ]
Oda, Yoshinao [2 ]
Takahashi, Yusuke [2 ]
Fujiwara, Toshifumi [1 ]
Fujiwara-Okada, Yuko [1 ]
Hatano, Mihoko [1 ]
Nabashima, Akira [1 ]
Kamura, Satoshi [1 ]
Iwamoto, Yukihide [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Fukuoka 8128582, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka 8128582, Japan
基金
日本学术振兴会;
关键词
Ewing sarcoma/primitive neuroectodermal tumor; miR-125b; p53; Bak; Chemoresistance; CANCER-CELLS; MULTIDRUG-RESISTANCE; TARGETING BCL2; GROWTH-FACTOR; P53; GENE; SARCOMA; EXPRESSION; MICRORNA; PROLIFERATION; SUPPRESSOR;
D O I
10.1186/1475-2867-13-21
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Diverse functions of microRNAs (miRNAs), including effects on tumorigenesis, proliferation, and differentiation, have been reported, and several miRNAs have also been demonstrated to play an important role in apoptosis. In this study, we investigated the possible role that miRNAs may play in the development of chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor (EWS). Methods: We screened doxorubicin (Dox)-resistant EWS cells to identify any distinct miRNA sequences that may regulate the chemoresistance of EWS cells. The effects of miRNAs were evaluated using a chemosensitivity assay. The possible target genes of the miRNAs were predicted using a web-based prediction program. Results: We found miR-125b to be upregulated in two different Dox-resistant EWS cell lines. The upregulation of miR-125b was also confirmed in the EWS tumors having survived chemotherapy regimen which includes doxorubicin. When miR-125b was knocked down in EWS cells, both the Dox-resistant and parental cells showed an enhanced sensitivity to doxorubicin, which was associated with the upregulation of the pro-apoptotic molecules, p53 and Bak. Inversely, the overexpression of miR-125b in parental EWS cells resulted in enhanced drug resistance, not only to doxorubicin, but also to etoposide and vincristine. Conclusions: Our findings suggest that miR-125b may play a role in the development of chemoresistance in EWS by suppressing the expression of the apoptotic mediators, such as p53 and Bak.
引用
收藏
页数:14
相关论文
共 53 条
[1]   Ewing's sarcoma [J].
Balamuth, Naomi J. ;
Womer, Richard B. .
LANCET ONCOLOGY, 2010, 11 (02) :184-192
[2]   EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma [J].
Ban, Jozef ;
Bennani-Baiti, Idriss M. ;
Kauer, Max ;
Schaefer, Karl-Ludwig ;
Poremba, Christopher ;
Jug, Gunhild ;
Schwentner, Raphaela ;
Smrzka, Oskar ;
Muehlbacher, Karin ;
Aryee, Dave N. T. ;
Kovar, Heinrich .
CANCER RESEARCH, 2008, 68 (17) :7100-7109
[3]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[4]  
BIEDLER JL, 1973, CANCER RES, V33, P2643
[5]   MUTATIONS THAT LEAD TO REITERATIONS IN THE CELL LINEAGES OF C-ELEGANS [J].
CHALFIE, M ;
HORVITZ, HR ;
SULSTON, JE .
CELL, 1981, 24 (01) :59-69
[6]   Oncomirs - microRNAs with a role in cancer [J].
Esquela-Kerscher, A ;
Slack, FJ .
NATURE REVIEWS CANCER, 2006, 6 (04) :259-269
[7]   Mechanism of Cell Adaptation When and How Do Cancer Cells Develop Chemoresistance? [J].
Fodale, Valentina ;
Pierobon, Mariaelena ;
Liotta, Lance ;
Petricoin, Emanuel .
CANCER JOURNAL, 2011, 17 (02) :89-95
[8]   Macrophage Infiltration Predicts a Poor Prognosis for Human Ewing Sarcoma [J].
Fujiwara, Toshifumi ;
Fukushi, Jun-ichi ;
Yamamoto, Shunsaku ;
Matsumoto, Yoshihiro ;
Setsu, Nokitaka ;
Oda, Yoshinao ;
Yamada, Hisakata ;
Okada, Seiji ;
Watari, Kosuke ;
Ono, Mayumi ;
Kuwano, Michihiko ;
Kamura, Satoshi ;
Iida, Keiichiro ;
Okada, Yuko ;
Koga, Mihoko ;
Iwamoto, Yukihide .
AMERICAN JOURNAL OF PATHOLOGY, 2011, 179 (03) :1157-1170
[9]   Tumor resistance to apoptosis [J].
Fulda, Simone .
INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (03) :511-515
[10]   Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin [J].
Ganjavi, H ;
Gee, M ;
Narendran, A ;
Freedman, MH ;
Malkin, D .
CANCER GENE THERAPY, 2005, 12 (04) :397-406